(Reuters) – Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome.
The study is expected to enroll about 270 patients across countries, Alexion said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
